On Monday, Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ:TLRY) (TSX:TLRY), announced its contribution to an independent clinical trial to research the efficacy of medical cannabis as a treatment for glioblastoma, which is a severe form of brain cancer.
The clinical trial, to be conducted in Spain, will recruit 30 patients from eight specialized neuro-oncology medical sites.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased